Literature DB >> 9660943

Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.

P Kahlem1, H Green, P Djian.   

Abstract

Different proteins bearing polyglutamine of excessive length are lethal to neurons and cause human disease of the central nervous system. In parts of the brain affected by Huntington's disease, the amount of the huntingtin with expanded polyglutamine is reduced and there appear huntingtin-containing polymers of larger molecular weight. We show here that huntingtin is a substrate of transglutaminase in vitro and that the rate constant of the reaction increases with length of the polyglutamine over a range of an order of magnitude. As a result, huntingtin with expanded polyglutamine is preferentially incorporated into polymers. Both disappearance of the huntingtin with expanded polyglutamine and its replacement by polymeric forms are prevented by inhibitors of transglutaminase. The effect of transglutaminase therefore duplicates the changes in the affected parts of the brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660943     DOI: 10.1016/s1097-2765(00)80059-3

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  48 in total

1.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

2.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 3.  Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?

Authors:  D C Rubinsztein; A Wyttenbach; J Rankin
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

Review 4.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

Review 5.  Functional aspects of cellular microcompartmentation in the development of neurodegeneration: mutation induced aberrant protein-protein associations.

Authors:  Judit Ovádi; Ferenc Orosz; Susan Hollán
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

6.  Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor.

Authors:  M I Diamond; M R Robinson; K R Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

7.  Bistability explains threshold phenomena in protein aggregation both in vitro and in vivo.

Authors:  Theodore R Rieger; Richard I Morimoto; Vassily Hatzimanikatis
Journal:  Biophys J       Date:  2005-11-18       Impact factor: 4.033

8.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

Review 9.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

10.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.